摘要
背景:尽管粘膜炎、腹泻、便秘以及免疫抑制是公认的癌症治疗的副作用,其机制包括肠道菌群组成的变化和艰难梭菌感染却尚未彻底被阐明。 前言:本文查阅相关文献,综述了癌症化疗,放射治疗,和艰难梭菌相关性结肠炎之间的关系。 方法:对2008至2015年之间出版的英文文献,肿瘤化疗、放射治疗联合筛查,和艰难梭菌相关性结肠炎的关系进行综述。 结果:某些化疗的组合,主要是那些含有紫杉醇,更可能是由艰难梭菌感染(CDI)的,而另一些类型的肿瘤更易并发CDI化疗后。CDI照射后大多发生在患者接受治疗的癌症,在头部和颈部区域。风险因素发现质子泵抑制剂、抗生素、抗癌药物、管料。对于中度CDI轻度首次发作的首选药物是甲硝唑,而万古霉素保留严重CDI的初始集。fidaxomycin是重症治疗CDI的另一种选择,以减少复发。 结论:超声对肿瘤患者治疗的影响还没有完全承认。艰难梭菌感染患者抗生素治疗的同时,化疗更频繁。积极的支持性护理,静脉注射水化,抗生素,密切的手术监测选择性干预,可以显着降低发病率和危及生命的并发症与这种感染。
关键词: 难辨梭状芽孢杆菌,抗生素,化疗,放射治疗,靶向治疗,医院腹泻。
Current Medicinal Chemistry
Title:Clostridium difficile Infection: Associations with Chemotherapy, Radiation Therapy, and Targeting Therapy Treatments
Volume: 23 Issue: 39
Author(s): Avi Peretz, Izhar Ben Shlomo, Orna Nitzan, Luigi Bonavina, Pmela M. Schaffer, Moshe Schaffer
Affiliation:
关键词: 难辨梭状芽孢杆菌,抗生素,化疗,放射治疗,靶向治疗,医院腹泻。
摘要: Background: Although mucositis, diarrhea, and constipation as well as immunosuppression are well recognized side-effects of cancer treatment, the underlying mechanisms including changes in the composition of gut microbiota and Clostridium difficile infection have not yet been thoroughly reviewed.
Objective: We herein set out to review the literature regarding the relations between cancer chemotherapy, radiation treatment, and Clostridium difficile-associated colitis.
Method: Review of the English language literature published from 2008 to 2015 on the association between cancer chemotherapy, radiation treatment, and C. difficile-associated colitis.
Results: Certain chemotherapeutic combinations, mainly those containing paclitaxel, are more likely to be followed by C. difficile infection (CDI), while some tumor types are more likely to be complicated by CDI following chemotherapy. CDI following irradiation occurs mostly in patients who were treated for cancer in the head and neck area. Risk factors found were proton pump inhibitors, antibiotics, cytostatic agents, and tube feeding. The drug of choice for an initial episode of mild-to-moderate CDI is metronidazole, whereas vancomycin is reserved for an initial episode of severe CDI. Fidaxomycin is another option for treatment of severe CDI, with fewer recurrences.
Conclusion: The influence of CDI on the treatment of oncological patients is not fully acknowledged. Infection with C. difficile is more frequent in those patients treated by antibiotics simultaneously with chemotherapy. Aggressive supportive care with intravenous hydration, antibiotics, and close surgical monitoring for selective intervention can significantly decrease the morbidity and life-threatening complications associated with this infection.
Export Options
About this article
Cite this article as:
Avi Peretz, Izhar Ben Shlomo, Orna Nitzan, Luigi Bonavina, Pmela M. Schaffer, Moshe Schaffer , Clostridium difficile Infection: Associations with Chemotherapy, Radiation Therapy, and Targeting Therapy Treatments, Current Medicinal Chemistry 2016; 23 (39) . https://dx.doi.org/10.2174/0929867323666161028162018
DOI https://dx.doi.org/10.2174/0929867323666161028162018 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics Metabolism of the Novel IMP Dehydrogenase Inhibitor Benzamide Riboside
Current Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Hedgehog Knows Many Tricks
Current Drug Targets Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology Clinical Practice of Umbilical Cord Blood Stem Cells in Transplantation and Regenerative Medicine - Prodigious Promise for Imminent Times
Recent Patents on Biotechnology How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Mini-Reviews in Medicinal Chemistry Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Current Signal Transduction Therapy Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab
Current Rheumatology Reviews Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Bladder Cancer and Stem Cells
Current Signal Transduction Therapy MicroRNA Involvement in the Pathogenesis of Neuroblastoma: Potential for MicroRNA Mediated Therapeutics
Current Pharmaceutical Design Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Putative Mechanisms of Viral Transmission and Molecular Dysregulation of Mammary Epithelial Cells by Human Papillomavirus: Implications for Breast Cancer
Current Molecular Medicine